Coagulation/Hemostasis Analyzer Market

Coagulation/Hemostasis Analyzer Market Size (2022 to 2027)

The global coagulation/hemostasis analyzer market size is expected to be worth USD 4.84 billion by 2027, growing at a CAGR of 10.2% during the forecast period.

These analyzers are very much helpful in examining the hemostasis system in laboratories. Coagulometers are used in various methods, such as to observe blood clots in the blood. Coagulation analyzers follow easy steps to measure blood platelet levels. Therefore, the early diagnosis of the hemostasis system can prevent blood clots that might cause heart attacks. Most importantly, in very little time, coagulation analyzers can evaluate the thromboline and thromboplastin concentrations. Also, these analyzers are user-friendly as they can evaluate the required measurement in a few minutes, which helps prevent bleeding to blood clots.

Impact of covid-19 on the global coagulation/hemostasis market

Covid 19 has had a wide range of effects in various markets. The epidemic impacted the transport, production, and supply chains and made it difficult to get goods because of the government-imposed lockdowns and the stringent social distance laws. The healthcare sector was one of the markets that incurred losses due to these limitations. Because patients were the only thing that mattered, there were few experts, and no consideration was given to the other areas of healthcare. As a result, an economic crisis was faced, such as unemployment and a lack of resources at healthcare centers. In addition, the assessment, admission, and care of a covid patient were becoming more difficult with the continuous rise in patients. 

The pandemic, however, has had a comparatively positive impact on the hemostasis market. This positive impact is due to the usefulness of a coagulation analyzer in the severity of a covid patient's condition. The blood coagulation rate was used to predict the hematological and biochemical situation of the patient. Thus the devices helped analyze/predict and stabilize or provide immediate care to severe patients. Therefore, it was helpful in the diagnosis, and effective treatment of the virus leading to increased demand in the market during and pandemic and is expected to continue growing even in the post covid era.  

MARKET DRIVERS:

The major factor driving the growth of the global coagulation/hemostasis analyzer market is the rising number of cardiovascular problems worldwide.

Changes in lifestyles and increasing obesity cases due to changes in food habits are also some common factors propelling the growth rate of the coagulation/hemostasis market. In addition, creating awareness of the availability of diagnostics procedures to prevent heart attacks is enhancing the demand in this market. Furthermore, a growing number of people suffering from blood disorders is accelerating the market's growth rate. 

The preventive support of coagulation analyzers to support market growth.

Many coagulation/hemostasis analyzer tests and procedures can help determine the severity of several conditions in the body, like blood disorders, liver damage, infectious diseases, cholesterol levels, etc., all of which can be extremely helpful in the early diagnosis and treatment of several chronic conditions. Moreover, the analyzers also helped calculate the severity of covid patients during the pandemic, further boosting its presence and advantage in the healthcare systems. 

The focus on developing innovative techniques and the rise in the number of research centers in the biotechnology field is to create growth opportunities for the coagulation/hemostasis analyzers market. The increasing prevalence of automation equipment in laboratories is eventually significantly influencing the market's demand. The growing geriatric population is another factor in the market's growth rate. Constant economic growth in both developed and developing countries is lucratively surging market demand. Increasing investments in healthcare by private and public organizations are also positively impacting the market's growth.

MARKET RESTRAINTS:

Lack of standardization is slowly hindering the growth rate of the global coagulation/hemostasis analyzer market.

Automatic coagulation analyzers require massive amounts for installation and maintenance, which is remained a challenging factor for market developers. Strict rules and regulations by government organizations in approving medical equipment also impede the growth rate of the coagulation/hemostasis analyzers market. In addition, the availability of alternative devices that are highly advanced at a lower price is quietly limiting the market demand. Finally, people in rural areas are less aware of these techniques due to a lack of proper knowledge of the analyzers' utilization, degrading the market's growth rate.

REPORT COVERAGE:

This research report on the global coagulation/hemostasis analyzer market has been segmented and sub-segmented into the following categories.

Coagulation/Hemostasis Analyzer Market - By Test:

• ACT
• APT
• D Dimer Testing
• Platelet Function Test
• Prothrombin Time Testing
• Anti-Factor XA Test
• Heparin
• Protamine Dose-Response Test For ACT
• Fibrinogen Testing
• Other Coagulation Tests

Based on tests, prothrombin time testing has the largest market share in this segment. It is also the fastest-growing due to the increasing automation of this process in laboratories. The test can determine blood's proper clotting ability before major surgeries to avoid death due to bleeding. Surgical wounds need to heal correctly without problems; this test helps determine the same. It is helpful during liver transplant surgeries as it can also predict any liver diseases in the body. Therefore, the segment is showing progress with growing liver transplantations worldwide.

However, the fibrinogen testing segment is also expected to show fast growth during the forecast period due to its applications in testing blood loss disorder or excessive blood leakage without coagulation. The test measures the amount of fibrinogen in the body and helps diagnose the patient with any blood clotting disorders. 

Coagulation/Hemostasis Analyzer Market - By Product:

• POC Testing Analyzers
• Clinical Laboratory Analyzers

Clinical laboratory analyzers have the largest market in this segment based on product. The segment is high in revenue due to the ease of availability of clinical laboratory analyzers and their credibility. In addition, clinical analyzers are the most common testing sources and therefore dominate the market in availability, efficiency, and demand.

However, due to the rising demand for personalized care and treatment procedures, the POC testing analyzers segment is expected to show fast growth during the forecast period. In addition, the POC analyzers have different uses for testing blood sugar levels, cholesterol levels, abnormalities, and even the possibility of infectious diseases. Therefore, the multiple uses of the segment are expected to boost its growth during the forecast period. 

Coagulation/Hemostasis Analyzer Market - By End Users:

• Clinical Laboratories
• PoC

Based on end-users, Clinical laboratories have the largest share in the segment. The dominance of the market can be attributed to the fact that there is a massive influx of patients who get tested for coagulation/hemostasis in clinical laboratories setting. In addition, clinical laboratories are trustworthy and easy to access, and there has been a rise in the number of clinical laboratories worldwide, leading to the segment's revenue gain. 

However, the point of care systems is also gaining popularity due to the patient's focus shift towards personalized care and the rising availability of remote/home care services for patients who are unable to visit hospitals frequently. Therefore, POC's complete body analysis is now in demand, raising the segment's revenue. 

Coagulation/Hemostasis Analyzer Market - By Technology:

• Electrochemical
• Optical
• Mechanical

Based on technology, the Optical segment has the largest market share and is also the fastest-growing segment. The segment's dominance is due to its automated coagulation analyzer technique that uses optical density (O.D.) to measure blood clotting percentages. It is a fast, efficient, and reliable method of coagulation analysis and also very reliable due to efficient results. Therefore, it is the most common method of hemostasis analysis. 

The mechanical analyzers, however, are also expected to grow at a fast pace during the forecast period second to optical due to the method being automated and easy to perform with accurate results. 

Coagulation/Hemostasis Analyzer Market - By Region:

• North America
• Europe
• Asia-pacific
• Latin America
• The Middle East and Africa

Geographically, the North American Market is expected to hold the largest share of the global market and account for a 35.0% share in the global market during the forecast period. Factors such as increased lifestyle diseases such as obesity, diabetes, cardiovascular disorders, and the growing repetition of blood disorders are significant factors driving the North American market. In North America, the U.S. market is forecasted to lead during the forecast period, followed by Canada.

The European Market is expected to be the second-largest global coagulation/hemostasis analyzer market during the forecast period. The factors driving the European market in the European region are the growing aging population, Y-O-Y growth in the incidence rate of chronic blood diseases, inactive lifestyle changes, and rising blood-relevant disorders. The German market is predicted to dominate the European market during the forecast period.

The Asia-Pacific market is predicted to be the fastest-growing region in the global coagulation/hemostasis analyzer market. As a result of advancements in healthcare infrastructure in countries like China, Japan, and India, a growing number of general surgeries and an increasing number of research activities occurred in a few countries of the APAC region. Therefore, China is predicted to showcase the potential to grow by 12.7% in the forthcoming years.

The Latin American market is projected to perform well during the forecast period. Factors such as the growing number of people suffering from chronic blood disorders and an increasing number of hospitals and healthcare centers in Latin America are expected to boost the Latin American market growth. Moreover, growing investments in R&D activities and rising awareness among people regarding advanced technologies further foster the Latin American hemostasis analyzer market. In Latin America, the Brazilian market is expected to play the leading role during the forecast period.

The Middle East & Africa Market is expected to have a sluggish growth rate during the forecast period.

KEY MARKET PLAYERS:

Some of the notable participants dominating the Global Coagulation/Hemostasis Analyzer Market Profiled in the Report are Siemens AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Roche Diagnostics (Switzerland), Alere Inc. (U.S.), Sysmex Corporation (Japan), Helena Laboratories (U.S.), Instrumentation Laboratory (U.S.), International Technidyne Corporation (U.S.), Nihon Kohden Corporation (Japan) and Diagnostica Stago (France).

RECENT MARKET DEVELOPMENTS:

• In August 2022, future research examined aberrant coagulation markers and how they related to clinical outcomes in hospitalized, severely ill COVID-19 patients. The predictive significance of the aberrant coagulation parameters in COVID-19 is receiving increasing attention. Therefore, prothrombin concentration (P.C.), activated Partial thromboplastin time (aPTT), D-Dimer (D.D.), Anti Thrombin III (ATIII), and fibrinogen (Fg) along with hematological and biochemical parameters were investigated for their potential role in predicting COVID-19 patient severity and estimating their relationship to clinical outcomes in hospitalized and severe COVID-19 patients.
• InJanuary2021, HemoSonics Appreciates FDA Support for Viscoelastic Coagulation Analyzers for COVID-19 Patients and Highlights Quantra's Hemostasis Analyzer's Benefits. In response to COVID-19, HemoSonics appreciates FDA advice issued on January 14th that expands the use of viscoelastic coagulation analyzers in hospital patient healthcare settings. The FDA recommendation aims to increase the accessibility of coagulation equipment for measuring whole blood viscoelastic characteristics to evaluate hemostasis during the COVID-19 public health emergency. In individuals with COVID-19, hypercoagulability—an abnormally elevated risk for blood clotting—has been noted. 2 Clinical findings have demonstrated that blood coagulation problems are most likely brought on by the acute inflammatory response in individuals with severe COVID-19 infection.
• In March 2020, The Yumizen G200 hemostasis device from HORIBA Medical was approved for use with UK NEQAS BC samples. Research has demonstrated that lyophilized plasma samples from the U.K.'s National External Quality Assessment Scheme for Blood Coagulation (NEQAS BC) may be examined using HORIBA UK Ltd.'s Yumizen G200 hemostasis device. This demonstrates that the portable Yumizen G200 is reliable and appropriate for NEQAS BC testing, enabling laboratories to utilize the device for external quality evaluation.